Absolute Contraindications BPC-157 is not recommended for patients with: Active cancer (any type) theoretical concern regarding angiogenesis promotion Pregnancy or breastfeeding insufficient safety data Known hypersensitivity to any component of the formulation Relative Contraindications (Require Individualized Assessment) History of cancer after completion of treatment, a waiting period and oncology clearance may be appropriate Autoimmune disease especially if active or requiring immunosuppressive therapy Anticoagulant use injection site bleeding risk, though minimal with proper technique Severe renal or hepatic impairment dosing adjustments may be needed Monitoring and Follow-Up Patients on BPC-157 protocols are monitored through: Baseline and follow-up labs including inflammatory markers (CRP, ESR), complete blood count, and metabolic panel Clinical assessments pain scores, range of motion, functional outcomes at 2-week, 4-week, and 8-week intervals Imaging when indicated repeat ultrasound or MRI for musculoskeletal conditions to document structural healing The Patient Journey: What to Expect For patients considering peptide therapy, understanding the timeline of response helps set realistic expectations
We generally suggest wearing one patch per week
There is a large indeterminate zone between normal and abnormal levels (see Figure1: B 12 Test Result Review and Process Algorithm for Patients with Risk Factor for B 12 Deficiency* and/or Non- Specific** or Specific Symptom of B 12 Deficiency below)
Its ability to accelerate gut healing, decrease inflammation, regulate gut motility, and support a balanced gut microbiota highlights its value as a therapeutic peptide for both digestive function and health
This distribution pattern suggests the peptide follows physiological signals to areas of injury rather than accumulating indiscriminately
However, they appear to contain large quantities of vitamin B12 analogues
